Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aurixim in B-cell CD20+ Non-Hodgkin Lymphoma
NCT03057418Phase 1Completed
- Sponsor
- BioIntegrator LLC
- Start
- Jun 2013
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aurixim in non-Hodgkin lymphoma (NHL) and follicular lymphoma (FL), sponsored by BioIntegrator LLC. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Maximum Tolerated Dose at Day 36. Started Jun 2013; status: completed.
02
Drugs
aurixim
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03057418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057418.